Antibody Information
General Information of This Antibody (ID: ANTI0GYKVL)
| Antibody Name | chMC-813-70 |
|||||
|---|---|---|---|---|---|---|
| Organization | The Scripps Research Institute.; Academia Sinica. |
|||||
| Synonyms |
chMC-813-70
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Chimeric lgG |
|||||
| Antigen Name | Stage-specific embryonic antigen-4 (SSEA4) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
chMC-813-70-VC-PAB-MMAE [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.211 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Having ADCs with cleavable and non-cleavable linkers in place, we next assessed there in vitro cytotoxicity activities using SSEA4-expressing ovarian SKVO3 cells and breast cancer cells SKBR3 with a negligible expression of SSEA4 and 293T cells as a control. SK-OV3, SKBR3, and 293T cells (2×103 cells/well) were incubated with ADC-1, ADC-2, and chMC-813-70 for 72 h and then treated with MTS at 37 °C. The conversion of the tetrazolium salt MTS (3- (4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium) to a purple formazan, as a measure of the percentage of viable cells, was measured by absorbance at 490 nm after 4 h. The untreated cells' absorbance was considered 100 % survival (Figure 4).
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | SKOV-3 cells | CVCL_0532 | ||
References
